Asset

OXYCODEGOL

Nektar Therapeutics Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01619839phase2completed2012-06-012013-08-01Nektar TherapeuticsA Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
NCT03802227phase1terminated2018-10-222019-12-17Nektar TherapeuticsA Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)